Key result
MnSOD mimetic reduces doxorubicin-induced cardiotoxicity and oxidative stress in preclinical models.
Why the study?
Doxorubicin use is severely limited by dose-dependent cardiotoxicity, and effective strategies to prevent doxorubicin-induced cardiac injury remain limited. This study evaluated the cardioprotective effects of an engineered manganese superoxide dismutase mimetic against doxorubicin-induced cardiotoxicity.
Does an engineered manganese superoxide dismutase mimetic (MnSODm) attenuate doxorubicin-induced myocardial injury and oxidative stress in mice and H9C2 cardiomyocytes?
Does an engineered manganese superoxide dismutase mimetic (MnSODm) attenuate doxorubicin-induced myocardial injury and oxidative stress in mice and H9C2 cardiomyocytes?
Preclinical evidence demonstrates that an engineered manganese superoxide dismutase mimetic (MnSODm) attenuates doxorubicin-induced cardiotoxicity in mice and H9C2 cells by reducing oxidative stress and inflammation via Nrf2/HO-1 signaling.
Answers are grounded in this paper and cite their sources.
MnSODm may attenuate doxorubicin cardiotoxicity in animal models; leaves open clinical translation and requires human trials.
Doxorubicin (DOX) is a highly effective anticancer agent, but its clinical application is severely limited by dose-dependent cardiotoxicity. Despite its widespread use, effective strategies for preventing DOX-induced cardiac injury remain limited. In this study, we investigated the cardioprotective effects of an engineered manganese superoxide dismutase mimetic (MnSODm) against DOX-induced cardiotoxicity. MnSODm showed no significant cytotoxicity in H9C2 rat cardiomyocytes and dose-dependently alleviated DOX-induced cytotoxicity and morphological alterations, with optimal effects observed at 20 and 40 mg/L. MnSODm also reduced DOX-induced apoptosis, oxidative stress, and inflammatory responses in vitro. In a DOX-induced mouse model, MnSODm significantly improved cardiac index and reduced serum CK and LDH levels, histopathological abnormalities, and cardiac fibrosis. Moreover, MnSODm enhanced antioxidant defenses, as indicated by increased SOD, glutathione peroxidase, and catalase activities and reduced MDA levels. Mechanistically, MnSODm increased Nrf2 and HO-1 expression while reducing Keap1 expression, supporting the involvement of the Nrf2/HO-1 antioxidant pathway in its cardioprotective effects. MnSODm also attenuated inflammatory responses and preserved mitochondrial ultrastructure in DOX-treated cardiac tissue. Collectively, these findings demonstrate that MnSODm protects against DOX-induced cardiac injury, primarily through attenuation of oxidative stress and inflammation and modulation of the Nrf2/HO-1 antioxidant pathway, highlighting its potential as a cardioprotective strategy during DOX-based chemotherapy.
No takes yet. Share an insight, caveat, or question.
ZHAO et al. (2026) studied Doxorubicin-induced myocardial injury (cardiotoxicity) (n=108). Manganese superoxide dismutase mimetic (MnSODm, C40H57Mn2N9O21) vs. Doxorubicin model group, normal saline control, 0.5% CMC-Na vehicle control, and captopril positive control was evaluated on Doxorubicin-induced myocardial injury (cardiac index, serum CK and LDH, histopathology/fibrosis, oxidative stress markers, and Nrf2/HO-1 expression) (p=<0.001). Manganese superoxide dismutase mimetic (MnSODm) improved cardiac index and reduced serum CK and LDH levels and ROS accumulation in doxorubicin-induced cardiotoxicity models.
Synapse has enriched 10 related papers. Consider them for comparative context: